Cidara Therapeutics, Inc.
CDTX
Pozycja w akcjach
#3183
Cidara Therapeutics, Inc. is a biotechnology company specializing in the... Cidara Therapeutics, Inc. is a biotechnology company specializing in the creation, advancement, and commercialization of extended-duration anti-infective drugs. Their mission targets the prevention and treatment of infectious diseases and certain cancers within the U.S. Their primary therapeutic candidate, rezafungin acetate, is an innovative echinocandin antifungal designed to combat and avert severe fungal infections such as candidemia and invasive candidiasis, conditions known for their high fatality rates. Additionally, Cidara utilizes its Cloudbreak platform to engineer conjugated therapies aimed at preventing and treating influenza as well as various other viral illnesses, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), and SARS-CoV-2, the pathogen behind COVID-19. Originally incorporated in 2012 as K2 Therapeutics, Inc., the company adopted its current name, Cidara Therapeutics, Inc., in July 2014. Its operations are headquartered in San Diego, California.
Cena akcji
$221.38
Ostatnia synchronizacja: 2026-01-08
Kapitalizacja rynkowa
$5.61B
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
118.07%
Kraj
US
Handel Cidara Therapeutics, Inc. (CDTX)
Kategoria
Healthcare
EPS dla Cidara Therapeutics, Inc. (CDTX)
EPS na dzień September 2025 TTM: $-11.78
Według najnowszych raportów finansowych i ceny akcji firmy Cidara Therapeutics, Inc., obecny EPS (TTM) wynosi $-11.78. Na koniec roku 2023 firma miała EPS w wysokości $-5.25, spadek w porównaniu do do EPS z roku 2022, który wynosił $-9.61.
Historia EPS dla Cidara Therapeutics, Inc. od 2012 do 2026
EPS na koniec każdego roku
| Rok | EPS | Zmień |
|---|---|---|
| 2026 (TTM) | $-11.78 | -55.96% |
| 2024 | $-26.75 | 409.52% |
| 2023 | $-5.25 | -45.37% |
| 2022 | $-9.61 | -40.68% |
| 2021 | $-16.20 | -55.04% |
| 2020 | $-36.03 | 34.54% |
| 2019 | $-26.78 | -41.30% |
| 2018 | $-45.62 | -28.37% |
| 2017 | $-63.69 | -4.21% |
| 2016 | $-66.49 | 42.19% |
| 2015 | $-46.76 | -83.88% |
| 2014 | $-290.15 | 249.41% |
| 2013 | $-83.04 | 85.77% |
| 2012 | $-44.70 | 0.00% |
EPS dla podobnych firm lub konkurentów
| Firma | EPS | Różnica w EPS | Kraj |
|---|---|---|---|
| $17.32 | -247.03% |
US
|
|
| $-7.98 | -32.26% |
US
|
|
| $-5.29 | -55.09% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -335.48% |
NL
|
